Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA
- Development stage
- Phase 1
- Lead developer
- Chengdu Ucello Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This allogeneic, umbilical cord blood-derived chimeric antigen receptor T-cell (UCAR-T) therapy is a dual-targeting biologic developed by Chengdu Ucello Biotechnology for the treatment of refractory systemic lupus erythematosus (SLE). The therapy simultaneously targets CD19, expressed on B cells, and B-cell maturation antigen (BCMA), expressed on plasma cells. By depleting both B cells and long-lived plasma cells, the drug aims to eliminate the primary sources of pathogenic autoantibodies in SLE. As an allogeneic 'off-the-shelf' product derived from umbilical cord blood, it potentially offers faster access and more consistent manufacturing compared to autologous CAR-T therapies. It is currently being investigated in a Phase 1 clinical trial (NCT06274059) to evaluate its safety, tolerability, and preliminary efficacy in adult patients with refractory disease.
- Other names
- allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMACD19/BCMA UCAR-T
02
Targets
CD19 (B lymphocyte antigen CD19)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA.